Praxis Precision Medicines vs Protagonist Therapeutics

Praxis Precision Medicines (PRAX), health care, and Protagonist Therapeutics (PTGX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Praxis Precision Medicines is worth $8.5B on the stock market and Protagonist Therapeutics $8.1B: Praxis Precision Medicines is valued at 5% more. Over the past year Praxis Precision Medicines's share price has moved +68.5% and Protagonist Therapeutics's +47.9%.

Key facts

Praxis Precision Medicines market value
$8.5B
Protagonist Therapeutics market value
$8.1B
Protagonist Therapeutics P/E
26.4
Praxis Precision Medicines revenue
$0FY to 2025-12-31
Protagonist Therapeutics revenue
$46MFY to 2025-12-31
Superinvestors holding both
1

Market values as of .

Praxis Precision Medicines vs Protagonist Therapeutics: every measure side by side
Measure Praxis Precision Medicines Protagonist Therapeutics
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$8.5Bhigher$8.1Blower
Revenue$0lower$46Mhigher
Earnings-$303.3Mlower-$130.1Mhigher
Employees168higher149lower
Total assets$937.9Mhigher$668.2Mlower
Valuation
P/E—26.4
P/S—177
P/B6.8lower7.5higher
Dividend yield0.00%0.00%
Profitability
Operating margin—-344%
Balance sheet
Net assets$878.1Mhigher$614.7Mlower
Total liabilities$59.8Mhigher$53.5Mlower
Total debt——
Cash on hand$357.3Mhigher$128.4Mlower
Price change
Today-1.68%lower-0.13%higher
1 year+68.5%higher+47.9%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (1)

Praxis Precision Medicines only (1)

Protagonist Therapeutics only (2)

Percentages are each holding's share of that investor's reported portfolio (under "Both": Praxis Precision Medicines / Protagonist Therapeutics). Who owns PRAX · Who owns PTGX

Further comparisons

Learn

Questions and answers

Which is bigger, Praxis Precision Medicines or Protagonist Therapeutics?

By market value, Praxis Precision Medicines is the larger: $8.5B against $8.1B for Protagonist Therapeutics. By revenue in its latest fiscal year, Protagonist Therapeutics is the larger: $46M against $0 for Praxis Precision Medicines.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both Praxis Precision Medicines and Protagonist Therapeutics?

In their latest 13F filings, Polen Capital team holds both.

Cite this page

Funkfolio, “Praxis Precision Medicines vs Protagonist Therapeutics”, data as of 18 November 2026. https://funkfolio.com/compare/prax-vs-ptgx

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.